Economic evaluation for the US of durvalumab plus gemcitabine and cisplatin (DGC) in advanced biliary tract cancer (BTC)

被引：0
|
作者：
Aqel, Osama
Shen, Yunrong
Alfayoumi, Ibrahim
Abraham, Ivo
机构：
[1] Univ Arizona, Ctr Hlth Outcomes & Pharmacoecon Res, Tucson, AZ USA
[2] Univ Arizona Pharm, Dept Pharm Practice & Sci, Tucson, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4081
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Characterization of long-term survivors in the TOPAZ-1 study of durvalumab or placebo plus gemcitabine and cisplatin in advanced biliary tract cancer
    Finkelmeier, F.
    Bouattour, M.
    Valle, J. W.
    Vogel, A.
    Kim, J. W.
    Kitano, M.
    Chen, J. -S.
    Burris, H.
    Zaucha, R.
    Qin, S.
    Evesque, L.
    Zhen, D. B.
    Gupta, V. G.
    Park, J. O.
    Zotkiewicz, M.
    Rokutanda, N.
    Cohen, G.
    Oh, D. -Y.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 127 - 128
  • [32] EFFICACY AND SAFETY OF GEMCITABINE PLUS CISPLATIN CHEMOTHERAPY FOR ADVANCED BILIARY TRACT CANCER: A RETROSPECTIVE STUDY
    Hirano, G.
    Takii, Y.
    Kamihira, T.
    Fujisawa, K.
    Ichiki, Y.
    Suzuki, T.
    Matsuo, T.
    Uraoka, S.
    Aoki, K. -I.
    Sakai, K. -I.
    Ogawa, R.
    Higuchi, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 121 - 121
  • [33] Advanced Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin (GEMCIS) and Novel Inflammatory Markers
    Ali Ogul
    Mehmet Mutlu Kidi
    Mahmut Buyuksimsek
    Journal of Gastrointestinal Cancer, 2021, 52 : 294 - 299
  • [34] Advanced Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin (GEMCIS) and Novel Inflammatory Markers
    Ogul, Ali
    Kidi, Mehmet Mutlu
    Buyuksimsek, Mahmut
    JOURNAL OF GASTROINTESTINAL CANCER, 2021, 52 (01) : 294 - 299
  • [35] Comparison of gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer
    Park, Kwonoh
    Kim, Kyu-pyo
    Park, Seongjoon
    Chang, Heung-Moon
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (01) : 13 - 20
  • [36] Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC)
    Oh, D-Y.
    He, A. R.
    Qin, S.
    Chen, L-T.
    Okusaka, T.
    Vogel, A.
    Kim, J. W.
    Lee, T.
    Lee, M. A.
    Kitano, M.
    Burris, H. A.
    Bouattour, M.
    Tanasanvimon, S.
    Zaucha, R. E.
    Avallone, A.
    Cundom, J. E.
    Rokutanda, N.
    Zotkiewicz, M.
    Cohen, G.
    Valle, J. W.
    ANNALS OF ONCOLOGY, 2022, 33 : S1462 - S1463
  • [37] Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC)
    Oh, D. Y.
    He, A. R.
    Qin, S.
    Chen, L. T.
    Okusaka, T.
    Vogel, A.
    Kim, J. W.
    Suksombooncharoen, T.
    Lee, M. A.
    Kitano, M.
    Burris, H. A.
    Bouattour, M.
    Tanasanvimon, S.
    Zaucha, R. E.
    Avallone, A.
    Cundom, J. E.
    Rokutanda, N.
    Watras, M.
    Cohen, G.
    Valle, J. W.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S565 - S566
  • [38] Fluoropyrimidines plus Cisplatin versus Gemcitabine/Gemcitabine plus Cisplatin in Locally Advanced and Metastatic Biliary Tract Carcinoma - A Retrospective Study
    Croitoru, Adina
    Gramaticu, Julia
    Dinu, Ioana
    Gheorghe, Liana
    Alexandrescu, Sorin
    Buica, Florina
    Luca, Ioana
    Becheanu, Gabriel
    Herlea, Vlad
    Simionov, Iulia
    Hrehoret, Doina
    Lupescu, Ioana
    Popescu, Irinel
    Diculescu, Mircea
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2012, 21 (03) : 277 - 284
  • [39] 3.Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
    Randall Brand
    中国肿瘤临床, 2010, 37 (12) : 726 - 726
  • [40] A multicenter, phase Ib/2 study of varlitinib plus gemcitabine and cisplatin (gem/cis) for treatment of naive, advanced, or metastatic biliary tract cancer (BTC).
    Oh, Do-Youn
    Yong, Wei-Peng
    Chen, Li-Tzong
    Kim, Ji-Won
    Chang, Alex Yuang-Chi
    Park, Jin Hyun
    Hsieh, Chih-Yi
    Shih, Hsuan-Jen
    McIntyre, Nicola
    Chen, Ying-Chen
    Chang, Wei-Ling
    McHale, Mark
    Lindmark, Bertil
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
12345